Mulder
Overview
Mulder is a blockchain-powered software-as-a-service (SaaS) company specializing in end-to-end traceability of medical devices. Founded in 2023 by Michelle Kuei, Sriya Deokar, and Prathyusha Kadivella, Mulder is headquartered in London, United Kingdom. The company has successfully raised approximately $629,000 in pre-seed funding, led by SFC Capital and supplemented by Innovate UK grants. Mulder aims to address gaps in medical device traceability and compliance using blockchain technology.
Recent Developments
- January 2025: Mulder secured a €597,000 pre-seed funding round to enhance its blockchain technology, reflecting increased investor confidence. This round, led by SFC Capital, will accelerate Mulder's development and international expansion plans.
- November 2024: The company completed a fundraising event, gathering essential capital to further develop its platform. Key industry events also participated, emphasizing Mulder's growing influence in medtech circles.
- May 2024: Sriya Deokar and Prathyusha Kadivella were appointed as active directors, highlighting internal strategic realignments.
- April 2024: Mulder confirmed its operational status in compliance with UK company regulations, positioning itself as a front-runner in blockchain traceability solutions.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2023 |
| Headquarters | London, United Kingdom |
| Founders | Michelle Kuei, Sriya Deokar, Prathyusha Kadivella |
| Revenue | Under £632,000 |
| Key Investors | SFC Capital, Innovate UK |
| Industry | Healthcare Technology, Blockchain |
| Number of Employees | 5 |
Early History
Mulder was established in late 2023 amidst a rising demand for improved supply chain transparency in the medical device sector. The founders, hailing from diverse backgrounds in healthcare innovation, regulatory compliance, and technology development, quickly identified a niche in leveraging blockchain for device traceability. By addressing inefficiencies in existing methods, they laid the groundwork for what would become a crucial player in medtech SaaS applications.
Company Profile and Achievements
Mulder's business model revolves around utilizing blockchain technology to provide immutable and absolute visibility across the lifecycle of medical devices. Since its inception, it has made significant strides:
- 2023: Founded and registered in London, pioneering a blockchain solution tailored for medical device traceability.
- 2024: Raised $629,000 in capital, marking it as one of the promising startups in healthcare technology.
- 2025: The company is looking to scale operations beyond the UK, targeting markets in the US, EU, India, Japan, and Taiwan.
- Strategic Partnerships: Mulder has formed pivotal industry partnerships to pilot its technology, bringing key players on board to refine blockchain applications in traceability.
- Product Development: The leadership has successfully guided the company through a dynamic healthcare regulatory landscape, ensuring alignments with EU MDR and IVDR directives while innovating product features like real-time compliance monitoring.
Current Operations and Market Position
Mulder operates primarily within the healthcare technology sector, focusing on blockchain applications that offer advanced product lifecycle analytics and risk management. The company is poised for significant growth, capitalizing on increasing regulatory pressures for more transparent medical supply chains. By concentrating initially on SME manufacturers in the UK and planning an international reach, it aims to establish its architecture as industry-standard worldwide.
Conclusion
Mulder stands at the forefront of MedTech solutions, uniquely combining blockchain's immutable qualities with the intricate needs of medical device compliance and traceability. The company's growth trajectory and strategic financial injections position it as a transformative entity in healthcare systems, poised to influence both domestic and international markets profoundly. With an innovative core team and crucial initial funding, Mulder's potential within the medtech industry appears robust and promising.